New report shows life sciences sector using benefits to win talent war
New report shows life sciences sector using benefits to win talent war
Pharmaceutical companies in the UK are taking to offering improved benefits packages in order to keep hold of their top talent.
A salary survey from specialist life sciences recruiter, Clinical Professionals, revealed that the year on year salary breakdown in the life sciences sector shows little in the way of improvement in remuneration. However the benefits packages offered to employees have improved in every area, from medical cover to gym membership and even life assurance, as businesses attempt to keep their workforce satisfied while the sector slowly recovers from the recent economic downturn.
The report – the first of its kind for the industry - concludes that there has indeed been a slight increase in employee satisfaction, with more than half of those earning at least £49,000pa reported as happy with their salary (a slight drop from last year’s crossover point of £50,000pa.)
However, it seems that employers are still likely to face a battle to keep hold of talent, as over 50% of respondents in every field of life sciences (other than medical writing) are reported as looking for a new role. This was particularly prevalent within high end medical positions, as the report shows that 90% of those with a salary above £80,000pa are looking for a new position.
Clinical Professionals’ Group Managing Director, Yvette Cleland commented, “The salary survey shows us that, as the war for talent returns to the sector, companies are thinking imaginatively in order to keep their employees satisfied, and rather than raising salaries, improving benefits seems to be a popular option.”
The full report is available to view online: www.pharmaceuticalsalarysurvey.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.